{"id":10677,"date":"2026-02-23T23:02:28","date_gmt":"2026-02-23T23:02:28","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2026\/02\/23\/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown\/"},"modified":"2026-02-23T23:02:28","modified_gmt":"2026-02-23T23:02:28","slug":"biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2026\/02\/23\/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown\/","title":{"rendered":"STAT+: Novo\u2019s next-gen obesity drug stumbles in Lilly comparison study"},"content":{"rendered":"<p>    STAT+: Novo\u2019s next-gen obesity drug stumbles in Lilly comparison study<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>We\u2019ve got some big acquisition news today, and also some politics \u2014 specifically a look at how pharma lobbyists, who have longed considered the FDA something of a fortress, now see real opportunity to exert influence.<\/p>\n<p>Also, read up on a Phase 3 miss from Gossamer Bio, and why it\u2019s going to seek an approval anyway.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2026\/02\/23\/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2026\/02\/23\/biotech-news-novo-obesity-drug-stumbles-in-lilly-showdown\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Novo\u2019s next-gen obesity drug stumbles in Lilly comparison study Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. We\u2019ve got some big acquisition news today, and also some politics \u2014 specifically a look at how pharma lobbyists, who have longed considered the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-10677","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10677"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=10677"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10677\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=10677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=10677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=10677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}